Connetics Corporation, a specialty pharmaceutical company, engages in the development and commercialization of products for the medical dermatology market. It offers OLUX Foam for the treatment of scalp dermatoses, and scalp and non-scalp psoriasis; Soriatane, an oral retinoid, to treat severe psoriasis in adults; and Luxiq Foam, a midpotency topical steroid, for the treatment of mild-to-moderate steroid-responsive scalp dermatoses, such as psoriasis, eczema, and seborrheic dermatitis, as well as markets Evoclin for the treatment of acne vulgaris. The company also develops Desilux Foam and Primolux Foam, which completed Phase III clinical trials. Connetics sells its products primarily to physicians, principally dermatologists and pediatricians in North America. The company was incorporated in 1993 and is headquartered in Palo Alto, California. As of December 28, 2006, Connetics Corporation is a subsidiary of Stiefel Laboratories, Inc.